In a prospective cohort of 82 renal transplant recipients, we evaluated the capacity of the cytomegalovirus (CMV) load in whole blood (WB) to predict the plasma CMV load, aiming to identify active CMV infections by using WB samples only and to deduce a WB threshold. Using quantitative real-time PCR, a total of 1,474 WB samples were assayed, of which 279 were positive for CMV, and 140 out of the 276 paired plasma samples tested positive. Thirty (36.6%) patients presented with at least one positive plasma PCR result, and 21 infection episodes (19 patients) required curative treatment (median follow-up time, 12 months). When the plasma CMV load was >500 copies/ml (n ؍ 70), more than 94% (95% confidence interval, 86.0%, 98.4%) of WB samples had >500 copies/ml. Two prediction models were built: log 10 plasma viral load (VL) was calculated as ؊0.3777 ؉ 0.9342 ؋ log 10 WB VL and as ؊0.3777 ؉ 0.8563 ؋ log 10 WB VL for patients with and without treatment, respectively. In the validation sample (578 routine samples), 77.2% of the observed and expected plasma viral loads were concordant (95% confidence intervals, 73.5 and 80.5%). According to the model, the plasma viral load was >500 copies/ml when the WB load was >3,170 or >4,000 copies/ml in patients with or without treatment, respectively. WB seems to be an appropriate candidate for routine CMV monitoring of transplant recipients by using a single assay.Cytomegalovirus (CMV) remains a major opportunistic agent among transplant recipients, due to its direct and indirect effects and despite the use of different therapeutic strategies. While detection of CMV pp65 lower matrix protein (pp65 antigen [Ag]) has been widely performed for diagnosis of CMV infection, molecular assays based on quantitative PCR are now routinely used. Indeed, sensitive assays for the early detection of CMV infection are required for monitoring of patients and are essential for timely application of antiviral therapy (6,12,16,24,25,28,37).Commercial assays were first available for quantification of CMV DNA in plasma and peripheral blood leukocytes (PBL) (23,24,28,29,36). Then real-time PCR technology became available and represented a considerable improvement, since it was simpler, cheaper, and less time-consuming. In many laboratories, CMV infection diagnosis now relies on real-time PCR